Gerresheimer
Gerresheimer ampule production line. Photo - Gerresheimer

Gerresheimer announced profitable growth in the second quarter of 2020. “As a key supplier to the pharma and healthcare industry, we have significant responsibility for ensuring patients worldwide to receive the medication they need. We have guaranteed this over the past few months and maintained our delivery capacity at all times. New growth opportunities are now opening up for us in the pharma business. We are prepared for the strong demand for injection vials for the forthcoming vaccination campaigns and are additionally expanding capacity. As planned, we aim to maintain the growth which we saw in the second quarter. We are working continuously to implement our strategy for profitable and sustainable growth. To that end, we are investing in quality, capacity, digitalization, new markets, and smart new drug delivery products,” said Dietmar Siemssen, chief executive officer of Gerresheimer. Gerresheimer generated revenues of EUR 363 million (approximately Rs 3000 crore) in the second quarter of 2020, marking 4.6% organic growth in the core business compared to the same quarter of the prior year. photo – Gerresheimer…

Choose your subscription to read more

Trial

0 /mo
Not sure which package to choose? Try full access
  • ₹ 0 for 4 weeks*

PSA Plan 1

1500 /year
Access to the website, weekly eMail newsletter and monthly eMag
  • ₹1,500.00 for 1 year*

PSA Plan 2

2000 /Year
Print Copy, access to the website, weekly eMail newsletter and monthly eMag
  • ₹2000 for Year*

PSA Plan 3

3600 /2Year
Print Copy, access to the website, weekly eMail newsletter and monthly eMag
  • ₹3,600.00 for 2 year*